From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathway

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 11, 2010, Pages 5112-5117

  Giordano, Ricardo J ^a,e   Cardó Vila, Marina ^a   Salameh, Ahmad ^a   Anobom, Cristiane D ^b   Zeitlin, Benjamin D ^c   Hawke, David H ^a   Valente, Ana P ^b   Almeida, Fábio C L ^b   Nör, Jacques E ^c   Sidman, Richard L ^d   Pasqualini, Renata ^a   Arap, Wadih ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiogenesis; Cancer; Peptide; Retinopathy of prematurity; VEGFR

Indexed keywords

BEVACIZUMAB; MATRIGEL; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RETROLENTAL FIBROPLASIA; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG RESISTANCE; ENDOTHELIAL CELLS; HUMANS; LIGANDS; MICE; MOLECULAR SEQUENCE DATA; NEUROPILIN-1; PEPTIDE LIBRARY; PEPTIDES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINA; RETINAL NEOVASCULARIZATION; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950398570     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0915141107     Document Type: Article

References (46)

1. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186.
2. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
3. Arden GB, Sidman RL, Arap W, Schlingemann RO (2005) Spare the rod and spoil the eye. Br J Ophthalmol 89:764-769.
4. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932-936.
5. Loges S, Roncal C, Carmeliet P (2009) Development of targeted angiogenic medicine. J Thromb Haemost 7:21-33.
6. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangio genesis. Nat Rev Mol Cell Biol 8:464-478.
7. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
8. Crawford Y, Ferrara N (2009) VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res 335:261-269.
9. Gragoudas ES, et al. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816. (Pubitemid 40051904)
10. Rosenfeld PJ, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431. (Pubitemid 44511557)
11. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591.
12. Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14:6371-6375.
13. Fischer C, Mazzone M, Jonckx B, Carmeliet P (2008) FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942-956.
14. Carmeliet P, et al. (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-583. (Pubitemid 32448325)
15. Autiero M, et al. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9:936-943. (Pubitemid 36889938)
16. Luttun A, et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840.
17. Kaplan RN, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
18. Wu Y, et al. (2006) Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 12:6573-6584.
19. Pan Q, et al. (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11:53-67. (Pubitemid 46054517)
20. Zhang F, et al. (2009) VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 106:6152-6157.
21. Fischer C, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-475. (Pubitemid 350007692)
22. Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W (2001) Biopanning and rapid analysis of selective interactive ligands. Nat Med 7:1249-1253. (Pubitemid 33063782)
23. Giordano RJ, et al. (2005) Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem Biol 12: 1075-1083.
24. Falciani C, Lozzi L, Pini A, Bracci L (2005) Bioactive peptides from libraries. Chem Biol 12:417-426.
25. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W (2006) Display technologies: Application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 58:1622-1654.
26. Chorev M (2005) The partial retro-inverso modification: A road traveled together. Biopolymers 80:67-84.
27. Fischer PM (2003) The design, synthesis and application of stereochemical and directional peptide isomers: A critical review. Curr Protein Pept Sci 4:339-356.
28. Meister A (1965) Biochemistry of the Amino Acids (Academic, New York), 2nd Ed, Vol 1, pp 364.
29. Passaniti A, et al. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67:519-528.
30. Nör JE, et al. (2001) Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81:453-463.
31. Smith LE, et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111.
32. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905-909.
33. Lahdenranta J, et al. (2001) An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration. Proc Natl Acad Sci USA 98:10368-10373. (Pubitemid 32803026)
34. Heidary G, Vanderveen D, Smith LE (2009) Retinopathy of prematurity: Current concepts in molecular pathogenesis. Semin Ophthalmol 24:77-81.
35. Gerber HP, et al. (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 104:3478-3483.
36. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104:967-972. (Pubitemid 46154720)
37. Scheppke L, et al. (2008) Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 118:2337-2346.
38. Hajitou A, et al. (2006) A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125:385-398.
39. Landgren E, Schiller P, Cao Y, Claesson-Welsh L (1998) Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16:359-367. (Pubitemid 28052290)
40. von Wronski MA, et al. (2006) Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J Biol Chem 281: 5702-5710.
41. Starzec A, et al. (2006) Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 79:2370-2381.
42. Cébe-Suarez S, et al. (2008) Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB J 22:3078-3086.
43. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106:16157-16162.
44. Luttun A, Autiero M, Tjwa M, Carmeliet P (2004) Genetic dissection of tumor angiogenesis: Are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta 1654:79-94.
45. Dennis MS, et al. (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67:254-261.
46. 1H-15N HSQC experiments optimized to retain full sensitivity. J Magn Reson Series A 102:241-245.